Continued suppression of serum TSH level may be attributed to TSH receptor antibody activity as well as the severity of thyrotoxicosis and the time to recovery of thyroid hormone in treated euthyroid Graves patients

Yun Jae Chung, Byung Wan Lee, Ji Youn Kim, Jung Hwa Jung, Yong Ki Min, Myung Shik Lee, Moon Kyu Lee, Kwang Won Kim, Jae Hoon Chung

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

The cause of continued suppression of serum thyroid-stimulating hormone (TSH) levels during antithyroid drug therapy in some Graves' patients is unclear. Recently, there has been a notable explanation involving the direct inhibition of TSH receptor antibody (TRAb) on TSH secretion in the pituitary gland. The purpose of this study is to verify the relation between TRAb or other clinical parameters and the continued suppression of serum TSH level during antithyroid drug therapy in patients with Graves' disease. We reviewed the medical records of patients with Graves' disease between 1995 and 2002 at Samsung Medical Center. We selected 167 Graves' patients who had been euthyroid for at least 12 months after recovery of serum T3 and T4 levels during the antithyroid drug therapy. We analyzed the correlation of the interval until recovery of serum TSH with the pretreatment clinical parameters. We compared the recovery rates of suppressed TSH levels between pretreatment thyrotrophin-binding inhibitory immunoglobulin (TBII)-positive (> 15%) and TBII-negative patients. We also compared the clinical parameters between two groups at the time of diagnosis and after recovery of thyroid hormone. Pretreatment serum T3 level, 131I uptake, TBII activity, and the time to recovery of T3 or T4/free T4 level showed significant positive correlations with the interval until recovery of serum TSH level (p< 0.05). Recovery rates of serum TSH levels at 3 months after recovery of thyroid hormone were significantly lower in pretreatment TBII-positive patients than those in TBII-negative patients (p < 0.01). Serum TSH levels were significantly lower in TBII-positive patients at 3months after recovery of thyroid hormone (p < 0.05). TBII activities inversely correlated only with serum TSH levels at 3 months after recovery of thyroid hormone (p < 0.001). In conclusion, continued suppression of serum TSH level may be attributed to TRAb activity as well as the pretreatment severity of thyrotoxicosis and the time to recovery of thyroid hormone in patients with Graves' disease during antithyroid drug therapy.

Original languageEnglish
Pages (from-to)1251-1257
Number of pages7
JournalThyroid
Volume16
Issue number12
DOIs
Publication statusPublished - 2006 Dec 1

Fingerprint

Thyrotropin Receptors
Thyrotoxicosis
Thyrotropin
Thyroid Hormones
Antibodies
Serum
Immunoglobulins
Antithyroid Agents
Graves Disease
Drug Therapy

All Science Journal Classification (ASJC) codes

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Chung, Yun Jae ; Lee, Byung Wan ; Kim, Ji Youn ; Jung, Jung Hwa ; Min, Yong Ki ; Lee, Myung Shik ; Lee, Moon Kyu ; Kim, Kwang Won ; Chung, Jae Hoon. / Continued suppression of serum TSH level may be attributed to TSH receptor antibody activity as well as the severity of thyrotoxicosis and the time to recovery of thyroid hormone in treated euthyroid Graves patients. In: Thyroid. 2006 ; Vol. 16, No. 12. pp. 1251-1257.
@article{1f0a6c238b794b8e9fb31ad9e768f87f,
title = "Continued suppression of serum TSH level may be attributed to TSH receptor antibody activity as well as the severity of thyrotoxicosis and the time to recovery of thyroid hormone in treated euthyroid Graves patients",
abstract = "The cause of continued suppression of serum thyroid-stimulating hormone (TSH) levels during antithyroid drug therapy in some Graves' patients is unclear. Recently, there has been a notable explanation involving the direct inhibition of TSH receptor antibody (TRAb) on TSH secretion in the pituitary gland. The purpose of this study is to verify the relation between TRAb or other clinical parameters and the continued suppression of serum TSH level during antithyroid drug therapy in patients with Graves' disease. We reviewed the medical records of patients with Graves' disease between 1995 and 2002 at Samsung Medical Center. We selected 167 Graves' patients who had been euthyroid for at least 12 months after recovery of serum T3 and T4 levels during the antithyroid drug therapy. We analyzed the correlation of the interval until recovery of serum TSH with the pretreatment clinical parameters. We compared the recovery rates of suppressed TSH levels between pretreatment thyrotrophin-binding inhibitory immunoglobulin (TBII)-positive (> 15{\%}) and TBII-negative patients. We also compared the clinical parameters between two groups at the time of diagnosis and after recovery of thyroid hormone. Pretreatment serum T3 level, 131I uptake, TBII activity, and the time to recovery of T3 or T4/free T4 level showed significant positive correlations with the interval until recovery of serum TSH level (p< 0.05). Recovery rates of serum TSH levels at 3 months after recovery of thyroid hormone were significantly lower in pretreatment TBII-positive patients than those in TBII-negative patients (p < 0.01). Serum TSH levels were significantly lower in TBII-positive patients at 3months after recovery of thyroid hormone (p < 0.05). TBII activities inversely correlated only with serum TSH levels at 3 months after recovery of thyroid hormone (p < 0.001). In conclusion, continued suppression of serum TSH level may be attributed to TRAb activity as well as the pretreatment severity of thyrotoxicosis and the time to recovery of thyroid hormone in patients with Graves' disease during antithyroid drug therapy.",
author = "Chung, {Yun Jae} and Lee, {Byung Wan} and Kim, {Ji Youn} and Jung, {Jung Hwa} and Min, {Yong Ki} and Lee, {Myung Shik} and Lee, {Moon Kyu} and Kim, {Kwang Won} and Chung, {Jae Hoon}",
year = "2006",
month = "12",
day = "1",
doi = "10.1089/thy.2006.16.1251",
language = "English",
volume = "16",
pages = "1251--1257",
journal = "Thyroid",
issn = "1050-7256",
publisher = "Mary Ann Liebert Inc.",
number = "12",

}

Continued suppression of serum TSH level may be attributed to TSH receptor antibody activity as well as the severity of thyrotoxicosis and the time to recovery of thyroid hormone in treated euthyroid Graves patients. / Chung, Yun Jae; Lee, Byung Wan; Kim, Ji Youn; Jung, Jung Hwa; Min, Yong Ki; Lee, Myung Shik; Lee, Moon Kyu; Kim, Kwang Won; Chung, Jae Hoon.

In: Thyroid, Vol. 16, No. 12, 01.12.2006, p. 1251-1257.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Continued suppression of serum TSH level may be attributed to TSH receptor antibody activity as well as the severity of thyrotoxicosis and the time to recovery of thyroid hormone in treated euthyroid Graves patients

AU - Chung, Yun Jae

AU - Lee, Byung Wan

AU - Kim, Ji Youn

AU - Jung, Jung Hwa

AU - Min, Yong Ki

AU - Lee, Myung Shik

AU - Lee, Moon Kyu

AU - Kim, Kwang Won

AU - Chung, Jae Hoon

PY - 2006/12/1

Y1 - 2006/12/1

N2 - The cause of continued suppression of serum thyroid-stimulating hormone (TSH) levels during antithyroid drug therapy in some Graves' patients is unclear. Recently, there has been a notable explanation involving the direct inhibition of TSH receptor antibody (TRAb) on TSH secretion in the pituitary gland. The purpose of this study is to verify the relation between TRAb or other clinical parameters and the continued suppression of serum TSH level during antithyroid drug therapy in patients with Graves' disease. We reviewed the medical records of patients with Graves' disease between 1995 and 2002 at Samsung Medical Center. We selected 167 Graves' patients who had been euthyroid for at least 12 months after recovery of serum T3 and T4 levels during the antithyroid drug therapy. We analyzed the correlation of the interval until recovery of serum TSH with the pretreatment clinical parameters. We compared the recovery rates of suppressed TSH levels between pretreatment thyrotrophin-binding inhibitory immunoglobulin (TBII)-positive (> 15%) and TBII-negative patients. We also compared the clinical parameters between two groups at the time of diagnosis and after recovery of thyroid hormone. Pretreatment serum T3 level, 131I uptake, TBII activity, and the time to recovery of T3 or T4/free T4 level showed significant positive correlations with the interval until recovery of serum TSH level (p< 0.05). Recovery rates of serum TSH levels at 3 months after recovery of thyroid hormone were significantly lower in pretreatment TBII-positive patients than those in TBII-negative patients (p < 0.01). Serum TSH levels were significantly lower in TBII-positive patients at 3months after recovery of thyroid hormone (p < 0.05). TBII activities inversely correlated only with serum TSH levels at 3 months after recovery of thyroid hormone (p < 0.001). In conclusion, continued suppression of serum TSH level may be attributed to TRAb activity as well as the pretreatment severity of thyrotoxicosis and the time to recovery of thyroid hormone in patients with Graves' disease during antithyroid drug therapy.

AB - The cause of continued suppression of serum thyroid-stimulating hormone (TSH) levels during antithyroid drug therapy in some Graves' patients is unclear. Recently, there has been a notable explanation involving the direct inhibition of TSH receptor antibody (TRAb) on TSH secretion in the pituitary gland. The purpose of this study is to verify the relation between TRAb or other clinical parameters and the continued suppression of serum TSH level during antithyroid drug therapy in patients with Graves' disease. We reviewed the medical records of patients with Graves' disease between 1995 and 2002 at Samsung Medical Center. We selected 167 Graves' patients who had been euthyroid for at least 12 months after recovery of serum T3 and T4 levels during the antithyroid drug therapy. We analyzed the correlation of the interval until recovery of serum TSH with the pretreatment clinical parameters. We compared the recovery rates of suppressed TSH levels between pretreatment thyrotrophin-binding inhibitory immunoglobulin (TBII)-positive (> 15%) and TBII-negative patients. We also compared the clinical parameters between two groups at the time of diagnosis and after recovery of thyroid hormone. Pretreatment serum T3 level, 131I uptake, TBII activity, and the time to recovery of T3 or T4/free T4 level showed significant positive correlations with the interval until recovery of serum TSH level (p< 0.05). Recovery rates of serum TSH levels at 3 months after recovery of thyroid hormone were significantly lower in pretreatment TBII-positive patients than those in TBII-negative patients (p < 0.01). Serum TSH levels were significantly lower in TBII-positive patients at 3months after recovery of thyroid hormone (p < 0.05). TBII activities inversely correlated only with serum TSH levels at 3 months after recovery of thyroid hormone (p < 0.001). In conclusion, continued suppression of serum TSH level may be attributed to TRAb activity as well as the pretreatment severity of thyrotoxicosis and the time to recovery of thyroid hormone in patients with Graves' disease during antithyroid drug therapy.

UR - http://www.scopus.com/inward/record.url?scp=33846183780&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846183780&partnerID=8YFLogxK

U2 - 10.1089/thy.2006.16.1251

DO - 10.1089/thy.2006.16.1251

M3 - Article

C2 - 17199435

AN - SCOPUS:33846183780

VL - 16

SP - 1251

EP - 1257

JO - Thyroid

JF - Thyroid

SN - 1050-7256

IS - 12

ER -